您的购物车当前为空
NEO214, an autophagy inhibitor and a covalent conjugate of the PDE4 inhibitor Rolipram and perillyl alcohol, exhibits anti-cancer activity and blood-brain barrier (BBB) permeability. It prevents autophagy-lysosome fusion, blocking autophagic flux and triggering glioma cell death via mTOR activation and TFEB (Transcription Factor EB) aggregation. NEO214 inhibition of Macroautophagy/autophagy in glioblastoma cells may overcome chemotherapy resistance in glioblastoma [1].


为众多的药物研发团队赋能,
让新药发现更简单!
NEO214, an autophagy inhibitor and a covalent conjugate of the PDE4 inhibitor Rolipram and perillyl alcohol, exhibits anti-cancer activity and blood-brain barrier (BBB) permeability. It prevents autophagy-lysosome fusion, blocking autophagic flux and triggering glioma cell death via mTOR activation and TFEB (Transcription Factor EB) aggregation. NEO214 inhibition of Macroautophagy/autophagy in glioblastoma cells may overcome chemotherapy resistance in glioblastoma [1].
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 497 | 现货 | |
| 5 mg | ¥ 1,230 | 现货 | |
| 10 mg | ¥ 1,980 | 现货 | |
| 25 mg | ¥ 4,560 | 现货 | |
| 50 mg | ¥ 6,390 | 现货 | |
| 100 mg | ¥ 8,620 | 现货 | |
| 200 mg | ¥ 11,600 | 现货 | |
| 1 mL x 10 mM (in DMSO) | ¥ 1,360 | 现货 |
| 产品描述 | NEO214, an autophagy inhibitor and a covalent conjugate of the PDE4 inhibitor Rolipram and perillyl alcohol, exhibits anti-cancer activity and blood-brain barrier (BBB) permeability. It prevents autophagy-lysosome fusion, blocking autophagic flux and triggering glioma cell death via mTOR activation and TFEB (Transcription Factor EB) aggregation. NEO214 inhibition of Macroautophagy/autophagy in glioblastoma cells may overcome chemotherapy resistance in glioblastoma [1]. |
| 分子量 | 453.57 |
| 分子式 | C27H35NO5 |
| CAS No. | 1361198-80-2 |
| Smiles | C(OCC=1CC[C@H](C(C)=C)CC1)(=O)N2CC(CC2=O)C3=CC(OC4CCCC4)=C(OC)C=C3 |
| 存储 |
对于不同动物的给药剂量换算,您也可以参考 更多